Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Phio Pharmaceuticals ( (PHIO) ).
On June 25, 2025, Phio Pharmaceuticals announced that its Safety Monitoring Committee recommended advancing to the fifth dose escalation cohort in its Phase 1b clinical trial of PH-762, a treatment for certain skin cancers. The trial has shown a supportive safety profile with no serious adverse events reported, and Phio plans to complete enrollment in the final cohort by the third quarter of 2025, potentially enhancing its position in the cancer treatment market.
The most recent analyst rating on (PHIO) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology for immuno-oncology. The company’s lead clinical program, PH-762, targets the PD-1 gene to treat various forms of skin cancer, offering a potential non-surgical treatment option.
Average Trading Volume: 3,347,493
Technical Sentiment Signal: Sell
Current Market Cap: $10.41M
For a thorough assessment of PHIO stock, go to TipRanks’ Stock Analysis page.